Insulet Publishes Corporate Presentation on Omnipod Growth, AID Leadership, and Product Pipeline

Reuters
Feb 18
Insulet Publishes Corporate Presentation on Omnipod Growth, AID Leadership, and Product Pipeline

Insulet Corporation released an investor presentation highlighting Omnipod 5’s market position and global expansion, including 2025 revenue of $2.7 billion, more than 600,000 active customers, and presence in 25 global markets. The presentation notes the Omnipod Pod has an IP28 rating for up to 25 feet for 60 minutes, while the PDM and Controller are not waterproof. It also outlines product development plans, including Omnipod 5 ecosystem updates in 2026 and Omnipod 6 clinical study results and a 510(k) filing, as well as a fully closed-loop system for people with type 2 diabetes with a stated timeline of pivotal study start, filing, and launch. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insulet Corporation published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10